What Doctors Got Wrong About HRT for 20 Years

The Women's Health Initiative was designed in the early 1990s as a primary-prevention trial — a study of whether postmenopausal hormone therapy could reduce chronic disease risk in postmenopausal women over time. The estrogen-plus-progestin arm enrolled 16,608 women with an intact uterus and randomized them to a daily oral pill combining conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg), or to placebo. A separate arm enrolled 10,739 women with a prior hysterectomy and randomized them to oral conjugated equine estrogens alone, or to placebo. The trial began enrolling participants in 1993.

On July 7, 2002, the Data and Safety Monitoring Board halted the estrogen-plus-progestin arm early. The public communication that followed centered on a hazard ratio for invasive breast cancer of about 1.26 — interpreted as roughly an 8-case-per-10,000-women-per-year absolute increase in invasive breast cancer after several years of combination therapy. That number became the story. It also, as several of the trial's own investigators have since pointed out, did not actually reach the threshold for statistical significance the trial had set for itself.

The most direct account of how the announcement was constructed comes from Dr. Robert Langer, the WHI principal investigator at the Scripps Clinic site. In a 2017 CMAJ feature, he described the "highly unusual circumstances" surrounding the early termination and reporting, arguing that the initial results paper and accompanying press release — written rapidly by a small group of trial leaders — "resulted in misinformation and hysteria" rather than the careful, age-stratified communication the data could have supported. The two findings that were unambiguously real in the first results were an increase in venous thromboembolism and a reduction in hip fracture. The breast cancer headline was, at that moment, a trend, not a verdict.

The single most consequential design feature of the Women's Health Initiative is rarely the first thing women learn about it. The mean age of participants at enrollment was 63 — more than a decade past the typical age of natural menopause in the United States. Most participants were initiating hormones in their sixties or later, often for the first time in many years. The trial was a primary-prevention study of chronic disease in older postmenopausal women, not a symptom-relief study of women in or near the menopause transition.

That distinction is not a technicality. Cardiovascular biology is time-sensitive. In a woman who has been postmenopausal for fifteen years, the arteries have often already begun to accumulate atherosclerotic plaque, and introducing estrogen into a vascular environment that has already changed is not the same intervention as introducing it into one that has not. The same hormone, the same dose, in two different bodies, can produce two different stories.

What that design choice means for any reader trying to read the WHI today is straightforward. The findings travel honestly only when the population they came from travels with them. The reanalyses that followed — the ones that asked the trial's own data what happened when the picture was sorted by age and by time since menopause — are where the conversation gets useful for the women the trial was never really about.

Three studies, in order, tell the story.

In 2013, Dr. JoAnn Manson and the WHI investigators published a reanalysis of the trial by age at initiation and by time since menopause. The paper, titled Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials and published in JAMA, examined health outcomes across the full trial period and the years immediately after participants stopped taking hormones. The pattern that emerged was consistent: the absolute risks of adverse events were lower in women who initiated therapy at ages 50 to 59 than in women who started in their seventies, and the overall benefit-risk balance was meaningfully more favorable in the younger group.

In 2016, a different team published the first randomized controlled trial designed specifically to test the timing hypothesis the WHI reanalyses had pointed toward. The Early versus Late Intervention Trial with Estradiol — ELITE — randomized 643 healthy postmenopausal women without cardiovascular disease to oral 17β-estradiol or placebo, with participants stratified by whether they were less than six years or at least ten years past menopause. After up to seven years of treatment, the early-postmenopausal group on estradiol showed significantly slower progression of carotid intima-media thickness — a measure of subclinical atherosclerosis — than the placebo group. The late-postmenopausal group showed no such difference. The same hormone, two different time windows, two different vascular trajectories.

In 2017, Manson and the WHI investigators returned with an 18-year follow-up of more than 27,000 trial participants and 7,489 deaths through the end of 2014. The headline was, in some ways, the quietest finding in the whole story: across the full trial, hormone therapy was associated with no increase in all-cause, cardiovascular, or cancer mortality compared with placebo. Among women who had been 50 to 59 at randomization, the trend ran in the other direction — a roughly 30% lower all-cause mortality signal in the hormone-therapy group, framed by the investigators themselves as a directional finding in that age band rather than a statistically definitive subgroup result.

As Manson and her co-authors have emphasized in their 2024 JAMA review of the WHI clinical trials, the absolute risks of these hormones are much lower in early menopause than in later menopause — a sentence that captures, in plain language, what twenty years of reanalysis converged on. The when of initiation matters as much as the whether.

This is the part of the story that requires the most patience. The honest reading of the WHI breast cancer evidence is not that hormone therapy is safe, and not that it is dangerous. It is that "hormone therapy" is not one thing — and the two arms of the WHI itself told two different stories.

In the estrogen-plus-progestin arm, the long-term follow-up confirmed an increase in invasive breast cancer compared with placebo. The magnitude is modest in absolute terms — on the order of an extra handful of cases per 10,000 women per year of use — and it varies with duration, formulation, and the specific progestin involved. It is real, and it deserves to be taken seriously in any individual conversation about combination therapy in a woman with an intact uterus.

In the estrogen-alone arm — the women with prior hysterectomy who took conjugated equine estrogens without a progestin — the picture moved the other way. Dr. Rowan Chlebowski and the WHI investigators reported in JAMA Oncology in 2015 that estrogen alone was associated with a reduced incidence of invasive breast cancer compared with placebo, with a hazard ratio of approximately 0.77, and a lower mortality from breast cancer on longer follow-up. The estrogen-alone women in the WHI did not just avoid the harm the press conference had warned about. In aggregate, they appeared to do better than the placebo group.

That contrast is the point. Estrogen plus medroxyprogesterone acetate in a woman with an intact uterus is one intervention. Estrogen alone in a woman with a hysterectomy is a different one. Newer formulations using micronized progesterone rather than medroxyprogesterone acetate, transdermal estradiol rather than oral conjugated estrogens, and lower doses all sit on yet another part of the map.

None of this is a substitute for a personal conversation with a clinician who knows a reader's family history, personal medical history, BRCA status if relevant, and current health. It is a reframe of what the evidence base looks like when "hormone therapy" is allowed to mean more than the single regimen the 2002 press release was about.

Reading the source documents from the past few years — the trial papers, the position statements, the practice bulletins — what comes through is not radical change. It is calm restoration of a clinical picture that the 2002 headlines flattened.

The 2022 Hormone Therapy Position Statement of The North American Menopause Society — the current US clinical-society standard, with a panel that includes Manson among its authors — concludes that for healthy women younger than 60 or within 10 years of menopause onset, and with no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture. Hormone therapy remains the most effective treatment for hot flashes and night sweats, and for the genitourinary syndrome of menopause. The same statement is equally clear that for women who initiate therapy more than ten years from menopause onset, or who are older than 60, the benefit-risk balance is less favorable, with greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Both of those framings live in the same document.

The American College of Obstetricians and Gynecologists Practice Bulletin No. 141 on Management of Menopausal Symptoms, published in 2014 and reaffirmed in 2024, points in the same direction: systemic estrogen, with or without a progestin, is the most effective therapy for vasomotor symptoms, and the right approach for any individual woman is to use the lowest effective dose for the duration that fits her clinical picture.

Within that framing, the choices a clinician and a patient can actually make have expanded. A 2015 systematic review and meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that, compared with transdermal estrogen therapy, oral estrogen was associated with about a 63% higher risk of a first venous thromboembolism. The mechanistic explanation is straightforward — oral estrogen passes through the liver first and increases pro-coagulant factors, while a patch or gel of estradiol delivered through the skin does not — and the practical implication for a woman with cardiovascular risk factors is that the choice between a pill and a patch is not a cosmetic one.

Vaginal estrogen for the genitourinary syndrome of menopause is, in modern practice, a separate intervention rather than a smaller version of systemic therapy. Cohort and systematic-review evidence summarized in Obstetrics & Gynecology in 2023 shows minimal systemic absorption, and a 2024 meta-analysis in the American Journal of Obstetrics & Gynecology found no significant increase in breast-cancer recurrence or mortality among breast-cancer survivors who used vaginal estrogen, with longer-term safety in women on aromatase inhibitors still being studied.

As Dr. Stephanie Faubion, Medical Director of The Menopause Society, put it in a 2022 statement marking the 20th anniversary of the WHI: "a lot of women going through the menopause transition are suffering unnecessarily because of misrepresentation of the data from 20 years ago. It's important that women be presented with the benefits and risks on the basis of accurate data and then make the decision that is best for their specific situation in collaboration with their healthcare professionals."

On November 10, 2025, the U.S. Food and Drug Administration, in coordination with the Department of Health and Human Services, announced that it was initiating the removal of the boxed warnings on menopausal hormone therapy products that had been in place since 2003. The boxed warnings — the regulatory equivalent of a stop sign on a medication label — had cautioned about cardiovascular disease, breast cancer, and probable dementia. The new labels, to be rolled out across manufacturers over the months that followed, would carry age-specific guidance emphasizing benefits when therapy is initiated in healthy women within 10 years of menopause onset. FDA Commissioner Marty Makary, framing the change at the time, said that women and their physicians "should make decisions based on data, not fear."

It is worth being precise about what the FDA action does and does not do. It does not turn hormone therapy into a universally appropriate intervention. It does not erase the contraindications. It does not change the math for a woman with a current breast cancer, a recent clot, or a recent stroke. And the boxed warning for endometrial cancer on systemic estrogen-alone products remains in place for women with an intact uterus — because estrogen without a progestin in a woman with a uterus genuinely raises endometrial cancer risk, and that science has not changed.

What the action does do is bring the regulatory framing closer to the clinical literature that has been accumulating since the 2013 reanalyses. The black-box warning had been written for the trial as the public read it in 2002. The labels being rolled out now reflect the trial as the investigators have spent twenty years explaining it. Independent fact-checks have flagged that some of the official messaging around the change has slipped into overstating long-term benefits, and the modern clinical-society framing remains the calmer, more careful guide. The regulatory shift is real and meaningful. It is not a green light, and it is not a finish line.

The most useful thing this article can leave behind is not a recommendation. It is a tool for the conversation with a clinician who can actually look at an individual reader's history, examine her, and think with her. The list below is meant to be skimmed before that appointment — a structured way to bring what a clinician needs into the room.

• The symptoms I am having — vasomotor (hot flashes, night sweats), sleep, mood, cognitive, urogenital, joint, sexual — and roughly how long each has been present.
• When my last menstrual period was, and whether my cycles have changed in length or flow over the past 12 months.
• My family history of breast cancer, ovarian cancer, venous thromboembolism (DVT, PE), stroke, cardiovascular disease, and dementia — and at what ages those occurred, when known.
• My own medical history of clotting disorders, cardiovascular events, migraine with aura, current or past cancers, liver disease, and gallbladder disease.
• My current medications, including anti-coagulants, anti-platelets, and any breast-cancer treatments past or current.
• Whether I still have a uterus, an intact cervix, and ovaries.
• Whether I have done genetic testing for BRCA or have a documented hereditary cancer syndrome.
• My current smoking, alcohol, and exercise patterns.
• The format and route I want to discuss — oral pill, transdermal patch, gel, ring, or local vaginal product — and why.
• The duration I am thinking about, and what would change my mind if the evidence shifts again.

This is a tool for a conversation, not a substitute for one. The clinician brings the clinical judgment. The reader brings the lived experience and the priorities. The list is just the bridge between them.